Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates Blog 对 FDA 新抗体-药物偶联物临床药理指南的思考 In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…Certara2024 年 5 月 10 日
Modeling and simulation in pediatric drug development Press Coverage Modeling and simulation in pediatric drug development Published: 2023 年 12 月 21 日 This is the article written in German, published on pharmind.Children's…Certara2023 年 12 月 21 日
American College of Toxicology 2025 Annual Meeting Conference American College of Toxicology 2025 Annual Meeting – – BoothCertara2023 年 5 月 24 日
Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease Case Study 转化药理学咨询支持治疗肺分枝杆菌复合病的联合疗法 RedHill Biopharma Ltd., a specialty biopharmaceutical company, developed RHB-204, a treatment for MAC, and needed…Certara2023 年 5 月 9 日
Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges On-Demand Webinar 治疗蛋白质的药物间相互作用:最新情况与挑战 Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…Certara2022 年 12 月 5 日
Why you should select your drug formulation before starting clinical studies Blog 为何应在开始临床研究前选择药物制剂 药物开发者常急于推进发现流程以进入人体试验。Most are…Certara2022 年 10 月 28 日
3 Takeaways from the FDA Oligo Guidance You Need to Know Blog 3 Takeaways from the FDA Oligo Guidance You Need to Know In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…Certara2022 年 9 月 23 日
The Essential Components of Your Drug’s Biomarker Strategy White Paper The Essential Components of Your Drug’s Biomarker Strategy Certara2022 年 1 月 14 日